Speech and Privacy Regulation in the World of Drugs and Healthcare
October 1, 2002Paula M. Stannard, Richard A. Samp, David G. Adams, William C. Waller
MR. WALLER: I’m the Chair of the Federalist Society’s Food and Drug Subcommittee and I’m welcoming you to Speech and Privacy Regulation in the World of Drugs and Healthcare. The Federalist Society for Law and Public Policy Studies is a group of conservatives and libertarians interested in the current state of the legal order. It is founded on the principle that the state exists to preserve freedom, that separation of powers is essential to our Constitution, and that it is emphatically the province of the judiciary to say what the law is and not what it should be. The Federalist Society seeks to promote both an awareness of these principles and to further their application through its activities and programs like this. This morning, we have two important topics to cover. The first is HIPAA and Privacy and the second is the First Amendment. Our plan is to have our speaker Paula Stannard and then proceed to the First Amendment panel. Paula graduated magna cum laude from Amherst College in 1987 and — I found this particularly interesting — she had her degree in political science and Latin. She received her J.D. from Stanford Law School, and she now serves as Counselor to the General Counsel of the U.S. Department of Health and Human Services, where she has worked on proposed bioterrorism legislation, regulatory reform initiatives, and of course the HIPAA privacy rule. So, without further adieu, Paula Stannard.